Melatonin as a Therapeutic Adjunct in Obstructive Sleep Apnea: A Review of Potential Benefits

Obstructive sleep apnea (OSA) is a prevalent sleep disorder characterized by recurrent upper airway obstruction, leading to intermittent hypoxia, sleep fragmentation, and increased risk of cardiovascular, metabolic, and neurocognitive complications. Chronic intermittent hypoxia (CIH), a hallmark of...

Full description

Saved in:
Bibliographic Details
Main Authors: Jose Javier Lasala, Don Eliseo III Lucero-Prisno
Format: Article
Language:English
Published: Korean Society of Sleep Medicine 2025-06-01
Series:Sleep Medicine Research
Subjects:
Online Access:http://sleepmedres.org/upload/pdf/smr-2025-02628.pdf
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849706323764051968
author Jose Javier Lasala
Don Eliseo III Lucero-Prisno
author_facet Jose Javier Lasala
Don Eliseo III Lucero-Prisno
author_sort Jose Javier Lasala
collection DOAJ
description Obstructive sleep apnea (OSA) is a prevalent sleep disorder characterized by recurrent upper airway obstruction, leading to intermittent hypoxia, sleep fragmentation, and increased risk of cardiovascular, metabolic, and neurocognitive complications. Chronic intermittent hypoxia (CIH), a hallmark of OSA, contributes significantly to oxidative stress, systemic inflammation, endothelial dysfunction, and neuronal injury. These mechanisms underlie the development of comorbidities such as hypertension, diabetes mellitus, dyslipidemia, and cognitive impairment. While continuous positive airway pressure is the standard treatment, poor adherence highlights the need for adjunctive therapies. Melatonin, a neurohormone with potent antioxidant, anti-inflammatory, and neuroprotective properties, has emerged as a promising therapeutic agent for mitigating CIH-related complications. Preclinical studies demonstrate that melatonin reduces oxidative stress and inflammation, improves endothelial function, and ameliorates metabolic dysfunction, including insulin resistance and lipid dysregulation. Additionally, melatonin has shown potential in preventing CIH-induced cognitive decline by reducing hippocampal oxidative damage, preserving synaptic plasticity, and enhancing neurogenesis. These neuroprotective effects may counteract the cognitive impairments frequently observed in OSA patients. This narrative review examines the impact of melatonin administration on cardiovascular, metabolic, and neurocognitive sequelae of OSA, focusing on its molecular mechanisms of action and therapeutic potential. While preclinical studies provide compelling evidence for its efficacy, clinical trials are needed to establish optimal dosing, safety, and long-term benefits of melatonin therapy in OSA patients. Integrating melatonin as an adjunctive therapy may offer a novel approach to reducing the burden of OSA-related diseases.
format Article
id doaj-art-7c2e7f0ad238449a84dac9933b72c4de
institution DOAJ
issn 2093-9175
2233-8853
language English
publishDate 2025-06-01
publisher Korean Society of Sleep Medicine
record_format Article
series Sleep Medicine Research
spelling doaj-art-7c2e7f0ad238449a84dac9933b72c4de2025-08-20T03:16:14ZengKorean Society of Sleep MedicineSleep Medicine Research2093-91752233-88532025-06-01162849210.17241/smr.2025.02628319Melatonin as a Therapeutic Adjunct in Obstructive Sleep Apnea: A Review of Potential BenefitsJose Javier Lasala0Don Eliseo III Lucero-Prisno1 University of the Philippines College of Medicine, Manila, Philippines Research and Innovation Office, Biliran Province State University, Naval, PhilippinesObstructive sleep apnea (OSA) is a prevalent sleep disorder characterized by recurrent upper airway obstruction, leading to intermittent hypoxia, sleep fragmentation, and increased risk of cardiovascular, metabolic, and neurocognitive complications. Chronic intermittent hypoxia (CIH), a hallmark of OSA, contributes significantly to oxidative stress, systemic inflammation, endothelial dysfunction, and neuronal injury. These mechanisms underlie the development of comorbidities such as hypertension, diabetes mellitus, dyslipidemia, and cognitive impairment. While continuous positive airway pressure is the standard treatment, poor adherence highlights the need for adjunctive therapies. Melatonin, a neurohormone with potent antioxidant, anti-inflammatory, and neuroprotective properties, has emerged as a promising therapeutic agent for mitigating CIH-related complications. Preclinical studies demonstrate that melatonin reduces oxidative stress and inflammation, improves endothelial function, and ameliorates metabolic dysfunction, including insulin resistance and lipid dysregulation. Additionally, melatonin has shown potential in preventing CIH-induced cognitive decline by reducing hippocampal oxidative damage, preserving synaptic plasticity, and enhancing neurogenesis. These neuroprotective effects may counteract the cognitive impairments frequently observed in OSA patients. This narrative review examines the impact of melatonin administration on cardiovascular, metabolic, and neurocognitive sequelae of OSA, focusing on its molecular mechanisms of action and therapeutic potential. While preclinical studies provide compelling evidence for its efficacy, clinical trials are needed to establish optimal dosing, safety, and long-term benefits of melatonin therapy in OSA patients. Integrating melatonin as an adjunctive therapy may offer a novel approach to reducing the burden of OSA-related diseases.http://sleepmedres.org/upload/pdf/smr-2025-02628.pdfobstructive sleep apneamelatoninoxidative stresscontinuous positive airway pressure
spellingShingle Jose Javier Lasala
Don Eliseo III Lucero-Prisno
Melatonin as a Therapeutic Adjunct in Obstructive Sleep Apnea: A Review of Potential Benefits
Sleep Medicine Research
obstructive sleep apnea
melatonin
oxidative stress
continuous positive airway pressure
title Melatonin as a Therapeutic Adjunct in Obstructive Sleep Apnea: A Review of Potential Benefits
title_full Melatonin as a Therapeutic Adjunct in Obstructive Sleep Apnea: A Review of Potential Benefits
title_fullStr Melatonin as a Therapeutic Adjunct in Obstructive Sleep Apnea: A Review of Potential Benefits
title_full_unstemmed Melatonin as a Therapeutic Adjunct in Obstructive Sleep Apnea: A Review of Potential Benefits
title_short Melatonin as a Therapeutic Adjunct in Obstructive Sleep Apnea: A Review of Potential Benefits
title_sort melatonin as a therapeutic adjunct in obstructive sleep apnea a review of potential benefits
topic obstructive sleep apnea
melatonin
oxidative stress
continuous positive airway pressure
url http://sleepmedres.org/upload/pdf/smr-2025-02628.pdf
work_keys_str_mv AT josejavierlasala melatoninasatherapeuticadjunctinobstructivesleepapneaareviewofpotentialbenefits
AT doneliseoiiiluceroprisno melatoninasatherapeuticadjunctinobstructivesleepapneaareviewofpotentialbenefits